Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Alimera Sciences is a drug manufacturers-specialty & generic business based in the US. Alimera Sciences shares (ALIM) are listed on the NASDAQ and all prices are listed in US Dollars. Alimera Sciences employs 145 staff and has a trailing 12-month revenue of around $54.1 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $2.70 |
|---|---|
| 52-week range | $2.03 - $7.92 |
| 50-day moving average | $2.97 |
| 200-day moving average | $5.02 |
| Wall St. target price | $10.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.97 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.7 from 2023-02-06
| 1 week (2023-02-01) | -4.26% |
|---|---|
| 1 month (2023-01-06) | -4.59% |
| 3 months (2022-11-08) | -46.32% |
| 6 months (2022-08-08) | -62.40% |
| 1 year (2022-02-04) | -37.21% |
|---|---|
| 2 years (2021-02-08) | -65.95% |
| 3 years (2020-02-07) | 6.9299 |
| 5 years (2018-02-07) | 16.95 |
| Revenue TTM | $54.1 million |
|---|---|
| Gross profit TTM | $52 million |
| Return on assets TTM | -14.84% |
| Return on equity TTM | 0% |
| Profit margin | -34.1% |
| Book value | $-5.33 |
| Market capitalisation | $18.9 million |
TTM: trailing 12 months
We're not expecting Alimera Sciences to pay a dividend over the next 12 months.
Alimera Sciences's shares were split on a 1:15 basis on 14 November 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alimera Sciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Alimera Sciences shares which in turn could have impacted Alimera Sciences's share price.
Over the last 12 months, Alimera Sciences's shares have ranged in value from as little as $2.03 up to $7.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alimera Sciences's is 1.3645. This would suggest that Alimera Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alimera Sciences, Inc. , a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.